New vaccines for tuberculosis

被引:245
|
作者
Kaufmann, Stefan H. E. [1 ]
Hussey, Gregory [2 ,3 ]
Lambert, Paul-Henri [4 ]
机构
[1] Max Planck Inst Infect Biol, Dept Immunol, D-10117 Berlin, Germany
[2] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa
[3] Univ Cape Town, Sch Child & Adolescent Hlth, ZA-7925 Cape Town, South Africa
[4] Ctr Med Univ Geneva, Ctr Vaccinol, Geneva, Switzerland
来源
LANCET | 2010年 / 375卷 / 9731期
基金
美国国家卫生研究院; 比尔及梅琳达.盖茨基金会;
关键词
HEPARIN-BINDING HEMAGGLUTININ; T-CELL SUBSETS; MYCOBACTERIUM-TUBERCULOSIS; IMMUNE-RESPONSES; MUTANT STRAIN; BOVIS BCG; VACCINATION; PROTECTION; EFFICACY; MEMORY;
D O I
10.1016/S0140-6736(10)60393-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
New vaccines are urgently needed if we want to reach the goal of substantially reducing the incidence of tuberculosis by 2050. Despite a steady increase in funding over the past decade, there is still a striking financial shortfall for vaccine research and development for tuberculosis. Yet, around ten vaccine candidates have left the laboratory stage and entered clinical trials. These vaccines are either aimed at replacing the present vaccine, BCG, or at enhancing immunity induced by BCG. However, these pre-exposure candidates are designed for prevention of disease and will therefore neither eradicate the pathogen, nor prevent stable infection. Long-term vaccination strategies need to target these more ambitious goals. Even though vaccine development will have a price, the return of investment will greatly exceed original costs.
引用
收藏
页码:2110 / 2119
页数:10
相关论文
共 50 条
  • [41] Will new tuberculosis vaccines provide protection against leprosy?
    Richardus, Jan Hendrik
    Saunderson, Paul
    Smith, Cairns
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2011, 15 (02) : 143 - 143
  • [42] Mycobacterium bovis BCG and New Vaccines for the Prevention of Tuberculosis
    Lahey, Timothy
    Von Reyn, C. Fordham
    MICROBIOLOGY SPECTRUM, 2016, 4 (05):
  • [43] What's Old and New in Tuberculosis Vaccines for Children
    Cranmer, Lisa M.
    Cotton, Mark F.
    Day, Cheryl L.
    Nemes, Elisa
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2022, 11 (SUPP 3) : S110 - S116
  • [44] New tuberculosis vaccines: advances in clinical development and modelling
    Weerasuriya, C. K.
    Clark, R. A.
    White, R. G.
    Harris, R. C.
    JOURNAL OF INTERNAL MEDICINE, 2020, 288 (06) : 661 - 681
  • [45] New vaccines enter fray in fight against tuberculosis
    Hannah Hoag
    Nature Medicine, 2004, 10 : 6 - 6
  • [46] Potential public health impact of new tuberculosis vaccines
    Ziv, E
    Daley, CL
    Blower, S
    EMERGING INFECTIOUS DISEASES, 2004, 10 (09) : 1529 - 1535
  • [47] Perspectives on Clinical and Preclinical Testing of New Tuberculosis Vaccines
    Dannenberg, Arthur M., Jr.
    CLINICAL MICROBIOLOGY REVIEWS, 2010, 23 (04) : 781 - +
  • [48] The use of mutant mycobacteria as new vaccines to prevent tuberculosis
    Pando, R. Hernandez
    Aguilar, L. D.
    Infante, E.
    Cataldi, A.
    Bigi, F.
    Martin, C.
    Gicquel, B.
    TUBERCULOSIS, 2006, 86 (3-4) : 203 - 210
  • [49] Prospects for elimination of childhood tuberculosis: the role of new vaccines
    Hatherill, Mark
    ARCHIVES OF DISEASE IN CHILDHOOD, 2011, 96 (09) : 851 - 856
  • [50] Moving new vaccines for tuberculosis through the regulatory process
    Brennan, MJ
    CLINICAL INFECTIOUS DISEASES, 2000, 30 : S247 - S249